NIBEC Co. Ltd Asset Resilience Ratio
NIBEC Co. Ltd asset resilience ratio. NIBEC Co. Ltd (138610) has an Asset Resilience Ratio of 0.59% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 138610 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of NIBEC Co. Ltd (2016–2025)
Asset resilience ratio of NIBEC Co. Ltd from 2016 to 2025. This chart shows how NIBEC Co. Ltd's Asset Resilience Ratio has changed over time. Read NIBEC Co. Ltd (138610) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down NIBEC Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of NIBEC Co. Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩381.07 Million | 0.59% |
| Total Liquid Assets | ₩381.07 Million | 0.59% |
Asset Resilience Insights
- Limited Liquidity: NIBEC Co. Ltd maintains only 0.59% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
NIBEC Co. Ltd Industry Peers by Asset Resilience Ratio
Compare NIBEC Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
NIBEC Co. Ltd Asset Resilience Ratio by Year (2016–2025)
NIBEC Co. Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for NIBEC Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 2.04% | ₩1.29 Billion ≈ $872.33K |
₩63.00 Billion ≈ $42.70 Million |
+0.87pp |
| 2024-12-31 | 1.17% | ₩730.00 Million ≈ $494.71K |
₩62.45 Billion ≈ $42.32 Million |
-7.96pp |
| 2023-12-31 | 9.13% | ₩6.10 Billion ≈ $4.13 Million |
₩66.80 Billion ≈ $45.27 Million |
-2.53pp |
| 2022-12-31 | 11.66% | ₩8.77 Billion ≈ $5.94 Million |
₩75.20 Billion ≈ $50.96 Million |
+4.64pp |
| 2021-12-31 | 7.02% | ₩3.74 Billion ≈ $2.54 Million |
₩53.28 Billion ≈ $36.11 Million |
-43.62pp |
| 2020-12-31 | 50.64% | ₩26.88 Billion ≈ $18.22 Million |
₩53.08 Billion ≈ $35.97 Million |
+23.91pp |
| 2019-12-31 | 26.74% | ₩9.56 Billion ≈ $6.48 Million |
₩35.73 Billion ≈ $24.22 Million |
+22.89pp |
| 2018-12-31 | 3.85% | ₩858.97 Million ≈ $582.11K |
₩22.32 Billion ≈ $15.12 Million |
-16.64pp |
| 2017-12-31 | 20.49% | ₩5.28 Billion ≈ $3.58 Million |
₩25.75 Billion ≈ $17.45 Million |
+0.37pp |
| 2016-12-31 | 20.13% | ₩4.62 Billion ≈ $3.13 Million |
₩22.97 Billion ≈ $15.57 Million |
-- |
About NIBEC Co. Ltd
NIBEC Co., Ltd., a healthcare company, engages in the manufacture and sale of dental bone grafts and tissue regenerative collagen products in South Korea and internationally. It offers dental ointment, peptide containing dental bone graft materials, regenerative biomaterials, tooth whitening, tooth desensitizer, herbal toothpaste, and cosmetic products. The company was founded in 2000 and is base… Read more